Lenard A Adler MD
Professor of Psychiatry and Child and Adolescent Psychiatry, NYU School of Medicine
Join to view full profile
530 1st AveNew York, NY 10016
Phone+1 212-263-3580
Dr. Adler is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Psychiatry, 1982 - 1986
Emory University School of MedicineClass of 1982
Certifications & Licensure
CT State Medical License 2021 - 2027
FL State Medical License 1994 - 2027
NJ State Medical License 2020 - 2027
NY State Medical License 1984 - 2027
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2013-2014
- Top Doctors: New York Metro Area Castle Connolly, 2008-2014
- Super Doctor SuperDoctors.com
Clinical Trials
Publications & Presentations
PubMed
- Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, P...Lenard A Adler, V Rose Lieberman, Leslie Brijbasi, Greg W Mattingly, Ilmiya Yarullina
The Journal of Clinical Psychiatry. 2026-05-27 - Correction: An Open‑Label Extension Study Assessing the Long‑Term Safety and Efficacy of Viloxazine Extended‑Release Capsules in Adults with Attention‑Deficit/Hyperact...Ann Childress, Andrew J Cutler, Lenard A Adler, Nicholas Fry, Kobby Asubonteng
CNS Drugs. 2026-05-01 - Reliability and convergent validity of the Japanese version of the Adult ADHD Investigator Symptom Rating Scale: a multicenter, longitudinal, non-interventional study.Akira Iwanami, Dan Nakamura, Kensuke Ito, Nobutaka Sakayoshi, Kentaro Yamato
Frontiers in Psychiatry. 2026-01-01
Press Mentions
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (Centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and OlderJuly 24th, 2026- Centanafadine Effective, ‘Clinically Meaningful’ for Adult ADHDJune 2nd, 2025
- What to Know About Adderall, Ritalin and Other Prescription StimulantsMarch 27th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
